MICHELE LOUGHREN: Open Payments
NPI 1881815231 · MICHIGAN CITY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,746 in 130 payments from 20 companies in 2025. Trend: 2023 $2,096 · 2024 $2,166 · 2025 $2,746
Food & beverage: $2,646Education: $100
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $405 |
| Lundbeck LLC | 13 | $263 |
| Neurocrine BioSciences, Inc. | 10 | $252 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $227 |
| Otsuka America Pharmaceutical, Inc. | 12 | $222 |
| Tris Pharma Inc | 12 | $199 |
| E.R. Squibb & Sons, L.L.C. | 13 | $195 |
| Teva Pharmaceuticals USA, Inc. | 5 | $166 |
| Alkermes, Inc. | 11 | $162 |
| Corium, LLC | 7 | $109 |
Products named: FANAPT, REXULTI, INGREZZA, CAPLYTA, Dyanavel XR, COBENFY, ARISTADA, Azstarys.
Industry payments across IN — which companies pay providers there.
